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Heroin is known to enhance catabolism and inhibit anabolism of purine nucleotides, leading to purine 
nucleotide deficiencies in rat brains. Here, we determined the effect of exogenous purine nucleotide 
administration on purine nucleotide metabolism in the brains of heroin-dependent rats. Heroin was 
administrated in increasing doses for 9 consecutive days to induce addiction, and the biochemical changes 
associated with heroin and purine nucleotide administration were compared among the treated groups. 
HPLC was performed to detect the absolute concentrations of purine nucleotides in the rat brain cortices. 
The enzymatic activities of adenosine deaminase (ADA) and xanthine oxidase (XO) in the treated rat 
cortices were analyzed, and qRT-PCR was performed to determine the relative expression of ADA, XO, 
adenine phosphoribosyl transferase (APRT), hypoxanthine-guaninephosphoribosyl transferase (HGPRT), 
and adenosine kinase (AK). Heroin increased the enzymatic activity of ADA and XO, and up-regulated 
the transcription of ADA and XO. Alternatively, heroin decreased the transcription of AK, APRT, and 
HGPRT in the rat cortices. Furthermore, purine nucleotide administration alleviated the effect of heroin 
on purine nucleotide content, activity of essential purine nucleotide metabolic enzymes, and transcript 
levels of these genes. Our findings therefore represent a novel, putative approach to the treatment of 
heroin addiction.
Uniterms: Purine nucleotide/quantitative analysis. Purine nucleotide/effects/brain rats. Heroin analysis. 
Adenosine deaminase analysis. Xanthine oxidase analysis
INTRODUCTION
Opiates, such as morphine and heroin, are illegally 
used as recreational drugs worldwide, and can significantly 
impair the user’s physical and mental health (Chu et al., 
2009; Li et al., 2014). Opioid dependence is a significant 
public health concern, underscoring the need for effective 
treatment options (Kresina, Bruce, Mulvey, 2013; Nutt, 
King, Phillips, 2010). Therefore, the exploration of 
the effects of repeated exposure to these compounds is 
important for understanding the mechanisms of drug 
dependency and developing new treatment options.
Properly regulated purine nucleotide (PN) 
metabolism is necessary for normal brain function 
(Franke, 2011). Imbalances in purine nucleotide levels 
lead to a variety of human diseases (Burhans, Weinberger, 
2007; El-Hattab, Scaglia, 2013; Kimura et al., 2003). 
Studies have shown that morphine and heroin can enhance 
the oxidation of xanthine and hypoxanthine in the lobus 
temporalis, lobus frontalis, and lobus parietalis of rats 
(Liu et al., 2007; Yang et al., 2006). Uric acid (UA) is the 
final oxidation product of purine metabolism in humans 
and higher primates, and changes in UA levels may reflect 
the catabolism of purine nucleotides (Liang, Clark, 2004). 
Furthermore, it has been reported that morphine may 
increase UA concentrations in the corpus striatum, as 
well as in serum and extracellularly, in vitro (Enrico et al., 
1997; Sumathi, Niranjali Devaraj, 2009). In patients where 
morphine was administered intracerebroventricularly for 
cancer-related pain, the UA levels in cerebrospinal fluid 
samples increased significantly (Goudas et al., 1999). 
Morphine may also increase ATP catabolic products, 
including nucleotides and oxypurines, in BALB/c mouse 
strains (Di Francesco et al., 1998). 
Previously, we have shown that opioids may lead to 
nucleotide metabolism disorders. Rats were administered 
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morphine (ip) over a period of 7 days in doses of 20, 30, 
45, 55, 65, 85, and 95 mg/kg, respectively, to induce 
morphine addiction (Liu et al., 2007). Rats also received 
heroin (ip) over a period of 9 days in doses of 3, 3.45, 
4.35, 5.7, 7.5, 9.75, 18.68, 17.16, and 21.12 mg/kg, 
respectively, to induce heroin addiction (Yang et al., 2006). 
Significant increases in UA concentration in plasma were 
observed in the rats following both morphine and heroin 
administration. The enzymatic activities of ADA and XO 
were found to be enhanced significantly in the brain and 
other organs of rats administered heroin, and morphine 
was shown to increase ADA and XO gene expression in 
the rat brain cortex (Liu et al., 2007; Yang et al., 2006). 
Our experiments using rat C6 glioma cells also 
revealed that the gene expression of HGPRT and AK, two 
key enzymes in the purine nucleotide salvage pathway, are 
down-regulated by morphine, indicating that morphine 
inhibits purine nucleotide anabolism (Liu, Hong, Zhao, 
2003). To further clarify the effects of heroin on purine 
nucleotide metabolism in vivo, we measured the absolute 
content of purine nucleotides in rat brain cortices by HPLC, 
and found that the levels of AMP and GTP are significantly 
reduced in rats administered heroin, resulting in a purine 
nucleotide deficiency (Li et al., 2011). Therefore, we 
hypothesize that purine nucleotide deficiency in the brain 
may be one of the biochemical mechanisms of heroin 
dependence. Thus, the goals of this study were to confirm 
that purine nucleotide metabolism disorders are induced 
by heroin, and to clarify whether purine administration 
can counteract the biochemical changes caused by heroin. 
MATERIAL AND METHODS 
Animals and Drug Treatment
Adult, male Wistar rats (n = 40, 180 ± 20 g) 
were obtained from the Jilin University Animal 
Laboratory (Changchun, China), housed under controlled 
environmental conditions with free access to food and 
water, and randomly divided into four groups. Each group 
included 10 animals, and heroin was administered twice 
a day at 12-h intervals. Group I served as the control 
group and rats in this group received normal saline (ip) 
for 9 days. Rats in groups II, III, and IV were treated with 
heroin, heroin+PN, and PN alone, respectively. Heroin 
was administrated (ip) in increasing daily doses of 0.5, 
0.75, 1.25, 2, 3, 4.25, 5.75, 5.75, and 5.75 mg/kg, for 9 
days (Li et al., 2009). PN was administrated by gavage at 
a constant dose of 30 mg/kg (AMP+GMP; in equimolar 
concentrations), 2 h before the administration of heroin 
for 9 days. On the morning of the 10th day, animals were 
killed via decapitation following ether-induced narcosis. 
Their brains were rapidly removed and thoroughly 
washed to remove the excess blood in ice-cold saline. The 
cortices were removed on a pre-cooled plate, snap frozen 
in liquid nitrogen, and stored at -80 °C. All experimental 
procedures were approved by the Experimental Animal 
Ethics Committee of Jilin University.
Reagents 
Heroin (99% purity) was obtained from the Public 
Security Office of Jilin province, China. Adenine and 
guanine nucleotides (ATP, AMP, GTP, and GMP) and 
the ion-pair reagent tetra butyl ammonium hydrogen 
sulfate (TBAHS) were purchased from Sigma. HPLC-
grade acetonitrile (ACN) and methanol were purchased 
from Fisher Scientific (Pittsburgh, PA, USA). All other 
chemicals used in this study were of analytical grade. 
Distilled water, filtered with a Milli-Q Academic Ultrapure 
Water System (Millipore, Bedford, MA, USA), was used 
to prepare the standard solutions and HPLC mobile phases. 
ADA and XO detection kits, and Coomassie blue protein 
detection kits, were purchased from Jinsite Biotechnology 
Co. Ltd. (Nanjing, China). PrimeScript RT Reagents Kits 
and SYBR PrimeScript RT-PCR kits were purchased from 
TaKaRa Biotechnology Co. Ltd. (Dalian, China). 
Content detection of purine nucleotides
Samples were analyzed with an Agilent 1100 HPLC 
system equipped with an autosampler, using Agilent 
Zorbsx SB-C18 (4.6×150 mm; 3.5 μm) columns. The 
mobile phase contained 10% methanol and 220 mmol/L 
KH2PO4, normalized to pH 6.5 with TBAHS. The flow 
rate of HPLC elution was 500 μL/min. The temperature 
of the column was 27±1 °C. The eluate was monitored at 
254 nm, with a sample size of 20 μL (Chen et al., 2007).
Cortex tissue (0.5 g) was removed from liquid 
nitrogen and pulverized in 4.5 mL cold, physiologic 
saline with a tissue pulping machine, at 12,000 rpm in 
an ice-water bath. The tissue samples were sonicated 
in 0.5 mL 6% HClO solution for 30 s in an ice-water 
bath, adjusted with TBAHS (4 mol/L) to pH 7.0, then 
centrifuged. The supernatant was filtered through 0.2 
pm 8-mm cellulose filters. The samples were injected 
directly into the HPLC column for PN measurement. 
By comparing retention times with pure GMP, AMP, 
GTP, and ATP, all compounds were chromatographically 
identified. Linearity was tested using five known standard 
solutions of increasing concentrations. Calibration curves 
were calculated by linear regression analysis of the peak 
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area vs. concentration for GMP, AMP, GTP, and ATP. The 
concentrations of GMP, AMP, GTP, and ATP in the rat 
cortex samples were calculated by plotting the peak area 
against the known standard concentrations.
Enzyme assays
The tissue homogenate was centrifuged at 3000 rpm 
for 10 min at 4 °C. The sedimented fraction was discarded, 
leaving only the supernatant, which represented 10% of 
the total tissue homogenate. Protein content was estimated 
using Coomassie blue protein detection kits. The activity 
of ADA and XO in the cortex samples were estimated 
using Guisti colorimetric and colorimetric detection kits, 
respectively (Li et al., 2011; Yang et al., 2006).
Evaluation of ADA, XO, HGPRT, APRT, and AK 
gene expression by qRT-PCR
Gene-specific primers were designed and a BLAST 
(NCBI) search was performed to ensure their specificity to 
the target mRNA transcript. The primers were synthesized 
by the Jinsite Corporation (Nanjing, China). The primer 
sequences for ADA, XO, HGPRT, APRT, AK, and β-actin 
are summarized in Table I.
Total RNA was extracted with Trizol (Gibco BRL, 
Grand Island, NY, USA), normalized to a final concentration 
of 500 ng/μL, and reverse transcribed using the PrimeScript 
RT Reagents Kit according to the manufactures instructions. 
qRT-PCR analyses were performed on an ABI Prism 7000 
Real Time PCR System (Applied Biosystems, Foster 
City，CA，USA), in a final volume of 20 μL, containing 
10 µL SYBR Premix Ex Taq, 0.4 µL of each primer, 0.4 
µL ROX Reference Dye, 2 µL RT product, and 6.8 µL 
dH2O, using the SYBR PrimeScript RT-PCR kit. The 
following qRT-PCR cycling conditions, recommended by 
the manufacturer, were used: 95 °C for 30 sec, followed 
by 40 cycles at 95 °C for 5 sec and 60 °C for 31 sec. All 
samples were run in 96-well optical plates in duplicate. The 
cycle threshold values (Ct) were calculated and exported to 
Microsoft Excel for analysis. Quantification was performed 
by experimental determination of Ct, defined as the cycle 
at which the fluorescence exceeds 10 times the standard 
deviation of the mean baseline emission for the early cycles 
(Collantes-Fernandez et al., 2002). The Pfaffl mathematical 
model was used for qRT-PCR data analyses (Pfaffl, 2001). 
β-actin was used as a reference gene.
Statistical analyses 
The data were analyzed and expressed as mean 
± SD. Statistical analyses were performed using SPSS 
18.0. Analysis of Variance (ANOVA) and post hoc SNK-q 
tests were performed to examine differences between the 
groups. Significance was applied to values of 0.05 or 0.01 
confidence. 
RESULTS AND DISCUSSION 
ADA and XO enzyme activity in rat cortices
The mean total protein content of the homogenates 
of the four groups (saline, heroin, heroin+PN, and PN) 
TABLE I - Primer sequences for real-time PCR




β-actin Forward AAGAGAGGCATCCTGACCCT 218 NM_031144
Reverse TACATGGCTGGGGTGTTGAA
ADA Forward AAAGGAAGGCGTGGTGTA 165 NM_130399
Reverse ATGCCGAATGCTTGCTCT
XO Forward AAGATCCGAAACGCCTGTGTG 132 NM_017154
Reverse GGAATCCTGGTGCGGTACAAAC
HGPRT Forward TCCTCATGGACTGATTATGGACA 132 NM_012583
Reverse TAATCCAGCAGGTCAGCAAAGA
APRT Forward TCCACGCACGGCGGCAAGAT 148 NM_001013061
Reverse AGGAGGCTGATACAGTGGG
AK Forward GCCGAAGACAAGCACAAG 167 NM_012895
Reverse CCGAACTTATCTATCCCAAT
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were 6.2 ± 0.2, 6.3 ± 0.4, 6.4 ± 0.6 and 6.2 ± 0.3 g/L, 
respectively, which indicates that there was no significant 
difference in the total tissue protein concentrations (P 
>0.05). The mean ADA activity of the saline, heroin, 
heroin+PN, and PN groups was 6.5 ± 0.8, 8.8 ± 0.9, 6.6 
± 0.8 and 6.3 ± 0.7 g/L, respectively, indicating that the 
administration of heroin significantly increases cortex 
ADA activity as compared with that in the saline group 
(P<0.05; Figure 1), and that PN administration cancels out 
the increased ADA activity induced by heroin (P<0.05).
The mean XO enzyme activity of each of the four 
groups was 11.5 ± 1.2, 14.3 ± 1.2, 12.2 ± 1.0, and 11.7 ± 1.3 
g/L, respectively. The XO activity of the heroin group was 
significantly higher than that of the saline group (P<0.05; 
Figure 1). The cortex XO activity of the heroin+PN 
group was significantly less than that of the heroin group 
(P<0.05). PN administration alone did not result in any 
significant difference in the examined enzyme activity as 
compared to the control (P>0.05).
ADA and XO are essential enzymes for purine 
catabolism. ADA irreversibly catalyzes the hydrolysis 
of adenosine to inosine. Inosine is then deribosylated 
by purine nucleoside phosphorylase, converting it to 
hypoxanthine (Cristalli et al., 2001). XO catalyzes 
the oxidation of hypoxanthine and xanthine to UA. 
Previously, our research showed that the ADA and XO 
levels in many tissues of rats administered heroin in vivo 
are elevated, and the effects of heroin on the brain persist 
for a longer time than in other tissues (P<0.05; Yang et 
al., 2006). These results indicate that heroin increases the 
ADA and XO levels in the cortex, and leads to increased 
purine nucleotide catabolism. This study shows that the 
administration of purine nucleotides, in combination with 
heroin, reduces ADA and XO levels dramatically (P<0.05) 
as compared with the group receiving only heroin, and 
indicates that increased purine nucleotide catabolism 
resulting from heroin administration, is negated by 
exogenous purine nucleotide administration. 
mRNA transcript levels of key purine nucleotide 
metabolic enzymes
The ADA and XO mRNA levels in cortex tissue 
were significantly higher in the group administered 
with heroin alone, as compared with those in the saline-
treated group (P<0.01). ADA and XO mRNA levels in 
the heroin+PN group, however, were significantly less 
than those in the heroin-treated group (P<0.05, P<0.01; 
Figure 2). As shown in Figure 3, AK mRNA levels 
were significantly lower in the group administered with 
heroin alone, as compared with that in the saline-treated 
control group (P<0.01). APRT and HGPRT mRNA levels 
were also significantly lower in the heroin-only group 
(P<0.01). The mRNA levels of HGPRT, APRT, and AK 
in the heroin+PN group were higher than those in the 
heroin-only group (P<0.05). 
Our data show significant increases in the ADA 
and XO mRNA levels in the cortices of rats administered 
with heroin alone, as compared with those in the control 
group that received only saline. Our results also show that 
these increases were counteracted by purine nucleotide 
administration. Furthermore, we found that the tendency 
of ADA and XO mRNA levels to change is correlated with 
the activity of the corresponding enzyme. Therefore, we 
conclude that the effect of heroin on purine nucleotide 
metabolism is dependent on the level of gene expression. 
FIGURE 1 - ADA and XO activities in rat cortex. *P<0.05 vs. 
Saline. δP<0.05 vs heroin.
FIGURE 2 - Relative mRNA level of ADA and XO in rat cortex. 
Relative mRNA levels are normalized against β-actin. ** P<0.01 
vs. Saline. δP<0.05 vs Heroin. δδ P<0.01 vs heroin.
FIGURE 3 - Relative mRNA level of AK, APRT and HGPRT in 
rat cortex. Relative mRNA levels are normalized against β-actin. 
** P<0.01 vs. Saline. δP<0.05 vs heroin. δδP<0.01 vs heroin.
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Purine nucleotides are synthesized either from 
simple precursors by de novo synthesis through energetic, 
multistep reactions, or assembled from free purine 
bases like guanine, hypoxanthine, and adenine, through 
nucleotide salvage pathways (Camici et al., 2010). 
However, in some organs, including the brain, purine 
nucleotide synthesis relies exclusively on salvage 
pathways. Previously, our research showed that gene 
expression levels of HGPRT, AK, and APRT, essential 
enzymes in the purine nucleotide salvage pathway, are 
down-regulated by heroin both in vivo and in vitro (Li et 
al., 2011; Liu et al., 2007). HGPRT catalyzes the salvage 
of the purine bases hypoxanthine and guanine to produce 
nucleotides (Balasubramaniam, Duley, Christodoulou, 
2014). APRT recycles adenine, produced by the polyamine 
pathway, to AMP. AK catalyzes the phosphorylation of 
adenosine to produce AMP (Camici et al., 2010; Ipata et 
al., 2011). As no HGPRT, APRT, or AK enzyme activity 
detection kits were available, we examined the expression 
levels of the HGPRT, APRT, and AK genes by qRT-PCR. 
Our results reveal that heroin inhibits the transcription of 
these three key enzymes involved in the purine nucleotide 
synthesis pathway in the rat cortex, however, the inhibitory 
effects of heroin on these enzymes could be negated with 
the administration of exogenous purine nucleotides.
Content detection of purine nucleotides
Liquid chromatographic analyses were performed as 
previously described. Figure 4 shows the retention time 
and area of the peak of the mixed reference solutions. 
Figure 5 shows the calibration curve obtained from cortex 
tissue for the purine nucleotides. Figure 6 shows the HPLC 
chromatogram of cortex tissue.
These results show that the proportion of AMP and 
GTP in the heroin-treated group decreased significantly as 
compared to those in the saline-treated group (Table II). 
However, purine nucleotide administration significantly 
reduced the magnitude of the AMP decrease induced 
by heroin (P<0.05), and alleviated the decrease in GTP, 
although not significantly. 
To verify our hypothesis that heroin dependence 
results in purine nucleotide deficiency, we measured 
the ATP, GTP, AMP, and GMP contents in the treated 
rat cortices. The AMP and GTP content in the group 
administered heroin decreased significantly as compared 
with those in the saline-treated group, which indicates 
that heroin reduces the content of some purine nucleotides 
in brain. Purine nucleotide administration, however, 
alleviated the AMP deficit significantly (P<0.05), and also 
reduced the GTP deficiency, albeit to a lesser degree, in 
heroin-dependent rats. 
Purine nucleotides play an important role in DNA 
synthesis, energy metabolism regulation, protein synthesis 
and function, and enzymatic activity. Purines are also 
essential components of many coenzymes, including 
NAD and Coenzyme A, and signaling molecules like 
cAMP (Duval et al., 2013). However, the consequences 
of AMP and GTP deficiency in the brain are not yet clear. 
It has been reported that biochemical changes such as 
FIGURE 4 - HPLC chromatogram of mixed reference solution. From left to right the peaks are GMP, AMP, GTP, and ATP 
respectively.
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TABLE II - The contents of GMP, AMP, GTP, ATP in rat cortex
Saline Heroin Heroin+PN PN
GMP (mg/mL) 37.35±2.59 36. 21±2.26 38.42±2.38 41.53±4.71
AMP (mg/mL) 87.78±3.92 49.04±3.11* 64.34±2.17δ 92.69±5.12
GTP (mg/mL) 15.65±1.49 4.31±0.44* 5.26±0.83 17.83±2.45
ATP (mg/mL) 4.10±0.85 4.28±1.12 3.94±0.72 4.48±0.67
*P<0.05 vs Saline; δP<0.05 vs Heroin.
FIGURE 5 - Calibration curve obtained from cortex for purine nucleotides. Different concentrations of purine nucleotide (25 mg/
mL, 75 mg/mL, 125 mg/mL, 175 mg/mL, 225 mg/mL) were used for the experiment.
FIGURE 6 - HPLC chromatogram of cortex. From left to right the peaks are GMP, AMP, GTP, and ATP respectively.
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decreased GMP concentrations are associated with opioid 
dependence in humans (Mannelli et al., 2009). It has also 
been shown that opioid use may have toxic effects on 
the central and peripheral nervous systems, leading to 
irreversible, pathological cellular changes. Furthermore, 
heroin and other opioids have been shown to inhibit the 
synthesis of DNA and RNA in brain tissues (Avella et al., 
2010; McLaughlin, Zagon, 2012). Our results indicate 
that the effect of heroin on the metabolism of purine 
nucleotides may result in purine nucleotide deficiency in 
the brain, representing a putative biochemical mechanism 
of heroin addiction. Our results also show that external 
compensation of purine nucleotides alleviates the 
deficiency in purine nucleotides in rat cortices caused 
by heroin, although purine nucleotide administration 
alone does not alter purine nucleotide concentrations, 
essential enzyme activity, or the mRNA levels of these 
key enzymes. Thus, purine nucleotide administration may 
represent a novel, effective approach to treating heroin 
addiction.
CONCLUSIONS
Our data show that heroin promotes catabolism 
and inhibits anabolism of purine nucleotides in the rat 
cortex, resulting in a purine nucleotide deficit. However, 
the administration of exogenous purine nucleotides 
can reverse these changes in nucleotide metabolism. 
Although our results are preliminary, they indicate that 
the relationship between purine nucleotide metabolism 
and opioid addiction deserves further study. 
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